Assessment of the ability of the Privigen® purification process to deplete thrombogenic factor XIa from plasma.
about
Manufacture of immunoglobulin products for patients with primary antibody deficiencies - the effect of processing conditions on product safety and efficacyReduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment.Absence of in vitro Procoagulant Activity in Immunoglobulin Preparations due to Activated Coagulation Factors.Human plasma-derived immunoglobulin G fractionated by an aqueous two-phase system, caprylic acid precipitation, and membrane chromatography has a high purity level and is free of detectable in vitro thrombogenic activity.
P2860
Assessment of the ability of the Privigen® purification process to deplete thrombogenic factor XIa from plasma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Assessment of the ability of t ...... ogenic factor XIa from plasma.
@en
Assessment of the ability of t ...... ogenic factor XIa from plasma.
@nl
type
label
Assessment of the ability of t ...... ogenic factor XIa from plasma.
@en
Assessment of the ability of t ...... ogenic factor XIa from plasma.
@nl
prefLabel
Assessment of the ability of t ...... ogenic factor XIa from plasma.
@en
Assessment of the ability of t ...... ogenic factor XIa from plasma.
@nl
P2093
P2860
P356
P1433
P1476
Assessment of the ability of t ...... ogenic factor XIa from plasma.
@en
P2093
I El Menyawi
P2860
P356
10.1111/VOX.12119
P577
2013-12-13T00:00:00Z